Tuberculosis and respiratory diseases
-
Tuberc Respir Dis (Seoul) · Jan 2017
Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea.
Inhaled indacaterol (Onbrez Breezhaler), a long-acting β2-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-marketing surveillance study conducted to evaluate the real-world safety and effectiveness of indacaterol in the Korean population. ⋯ In real-life clinical practice in South Korea, indacaterol was well tolerated in COPD patients, and can be regarded as an effective option for their maintenance treatment.